Immuneering Co. (NASDAQ:IMRX) Given Average Recommendation of “Hold” by Analysts

Shares of Immuneering Co. (NASDAQ:IMRX) have been given a consensus rating of “Hold” by the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $12.80.

A number of brokerages have recently commented on IMRX. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price target on shares of Immuneering in a research note on Thursday, November 14th. Morgan Stanley lowered shares of Immuneering from an “equal weight” rating to an “underweight” rating in a research note on Friday. Finally, Chardan Capital reissued a “buy” rating and set a $13.00 price target on shares of Immuneering in a report on Wednesday, November 20th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in IMRX. Vanguard Group Inc. lifted its stake in shares of Immuneering by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 1,203,666 shares of the company’s stock valued at $3,479,000 after buying an additional 129,851 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Immuneering in the second quarter valued at about $492,000. Renaissance Technologies LLC bought a new position in shares of Immuneering in the second quarter worth about $447,000. Acadian Asset Management LLC purchased a new stake in shares of Immuneering during the second quarter worth about $67,000. Finally, HighTower Advisors LLC raised its stake in Immuneering by 21.4% during the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock valued at $132,000 after purchasing an additional 9,400 shares during the period. Institutional investors own 67.65% of the company’s stock.

Immuneering Price Performance

Immuneering stock opened at $1.64 on Friday. Immuneering has a one year low of $1.00 and a one year high of $8.41. The business’s fifty day moving average is $2.06 and its 200 day moving average is $1.69. The stock has a market capitalization of $50.77 million, a PE ratio of -0.83 and a beta of -0.33.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.